Sentences with phrase «on gene vectors»

Next Wave asked: If research on gene vectors can be used not only to further gene therapy but also — potentially — to aid in the development of biological weapons, should scientists be concerned about the potential applications of their research in genetics (as Joseph Rotblat suggested in a 19 Nov 1999 editorial in Science magazine?)

Not exact matches

The aim is to introduce into the shuttle a viral vector loaded with the gene that the cells of these patients lack, with a particular focus on targeting neurons.

In four tumors, the vector mapped to a section of chromosome 12 and turned on several genes implicated in cancer, the team reports tomorrow in Science.

Now, to enable widespread gene delivery throughout the central and peripheral nervous systems, Caltech researchers have developed two new variants of a vector based on an adeno - associated virus (AAV): one that can efficiently ferry genetic cargo past the blood - brain barrier; and another that is efficiently picked up by peripheral neurons residing outside the brain and spinal cord, such as those that sense pain and regulate heart rate, respiration, and digestion.

They supported a range of studies, from work on gene therapy tools (including adenovirus and rous sarcoma virus vectors) to development of a new vaccine for the deadly Marburg virus.

After preclinical studies, a gene therapy trial for SCID - X1 was initiated, based on the use of complementary DNA containing a defective γc Moloney retrovirus — derived vector and ex vivo infection of CD34 + cells.

From this they generated new cells in which the vector was integrated into any one of thousands of gene segments — with each segment glowing green when it was activated, or «switched on.»

Vaxwave ® is based on lymphocytic choriomeningitis virus (LCMV) and in this vector the gene encoding the LCMV envelope protein, normally responsible for virus entry into target cells, has been deleted and replaced with a target gene of interest.

Functional KL2 genes were delivered to the mice using lentiviral vectors, based on a crippled version of HIV that was first developed by Verma and Salk Institute colleagues in 1996.

The program will be packed with papers on biochromatography, downstream processing, QbD, monoclonal antibodies, plasmids, enzymes, vaccines, viral vectors for gene delivery, VLPs, and other biopharmaceuticals, chiral molecules, SFC, fine chemicals, peptides, proteins, oligonucleotides, APIs, natural products, batch, multi-column and continuous SMB processes, column technology and equipment, monoliths, new and improved stationary phases, membrane chromatography, regulatory aspects, and more!

As the level of gene activity knockdown associated with transgenic RNAi depends on the level of expression of the hairpin constructs, we generated a number of derivatives of our initial vector, called the «VALIUM» series, to improve the efficiency of the method.

He is one of the world's leading authorities in gene therapy, having developed a gene therapy vector, based on a stripped - down version of HIV, that successfully delivers genes for therapeutic purposes.

The technical evaluation of projects may require the provision of additional data such as information on the genetic modification of your mutant mouse line if applicable (e.g. affected gene, MGI ID of the gene, type of mutation, ES - cell line used, genetic background (e.g. number of backcross generations), safety level, description of DNA modification, vector, remaining non-recipient DNA, donor organism), mutant phenotype (s), special housing or care requirements, current sanitary status, and intellectual property rights (who generated the mouse line, owner of the mouse line)

The gene - targeting approach developed by Suzuki and his colleagues relies on the use of so - called helper - dependent adenoviral vector to deliver large mutation - free DNA molecules into cells.

Neal received his Ph.D. from the Molecular and Cellular Biology program at the University of Washington in 2005, where he worked in the laboratory of Dr. Dusty Miller, focusing on development of new viral vectors for use in gene therapy.

Glybera alipogene tiparvovec from uniQure (Amsterdam, The Netherlands), the first commercially available gene therapy in Europe, is based on an AAV1 vector carrying the human lipoprotein lipase (LPL) gene (5).

Studies on vector integrations are providing crucial information on vector biology, the dynamics of genetically modified cells, and the safety of gene therapy.

The Tol2 Gateway - Compatible Toolbox is based on the original Tol2kit generated by the Chi - Bin Chien lab (Kwan et al., 2007) and includes four promoters, six fluorophores with nonoverlapping emission spectra (N - and C - terminal tags for mTagBFP, TagRFPt, EGFP, mVenus, mCerulean3, mKOFP2) and empty vectors that have standard cloning sites or gateway compatible cloning sites for easy cloning of your genes of interest.